The Biogen study is a Phase II clinical research study of the drug aducanumab for individuals age 50-85 with early Alzheimer’s disease, including mild cognitive impairment.
Aducanumab is a human antibody that recognizes some forms of beta-amyloid. The primary objective of the study is to evaluate the efficacy of aducanumab in slowing cognitive and functional impairment. This drug is not FDA-approved and is investigational.
Click here for a one-page handout on Biogen.